December 20, 2011 - Press Release
Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
October 31, 2011 - Press Release
Intellikine Earns $4 Million in Milestone Payments for Initiation of Two Phase 1 Clinical Trials for IPI-145, a Potent Inhibitor of PI3Kdelta and PI3Kgamma
October
12, 2011 - Press Release
Intellikine Initiates Phase I Study of Targeted Cancer Therapuetics INK1117
July
12, 2011 - Press Release
Intellikine Appoints Greg Berk, M.D. as Chief Medical
Officer
February
10, 2011 - Press Release
Intellikine and the PKD Foundation Collaborate to Advance Next-Generation Therapies for Polycystic Kidney Disease
December
3, 2010 - Press Release
Intellikine and the Multiple Myeloma Research Consortium Initiate Phase I Trial of Targeted Drug INK128
July
8, 2010 - Press Release
Infinity and Intellikine enter agreement to develop oral therapies targeting PI3 Kinase Delta, Gamma
April
2,
2010 - Press Release
Intellikine Announces Presentations at the AACR Annual
Meeting
March
30, 2010 - Press Release
Multiple Myeloma Research Foundation (MMRF) Grants $1.0
Million Each to Intellikine, Inc. and Tragara Pharmaceuticals,
Inc. to Advance Next-Generation Therapies for Multiple Myeloma
February
23, 2010 - Press Release
Intellikine Appoints William Rohn to its Board of Directors
January
12, 2010
- Press Release
3D Structure of Key Drug Target Sheds Light on How to Design Better Drugs
January
5, 2010
- Press Release
Intellikine Initiates Phase I Clinical Trial for Targeted
Anticancer Drug INK128
July 8, 2009 - Press Release
Intellikine Completes $51 Million Financing